Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of rectal cobitolimod for induction and maintenance in left-sided ulcerative colitis
MOH_2022-03-06_010624Phase 3Not yet recruiting
- Sponsor
- InDex Pharmaceuticals
- Start
- Oct 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cobitolimod in autoimmune colitis (5 arms), sponsored by InDex Pharmaceuticals. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
cobitolimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2022-03-06_010624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-06_010624.